Global Systemic Scleroderma Treatment Market Size to grow

New York, United States, Oct. 26, 2022 (GLOBE NEWSWIRE) — According to a research report published by Spherical Insights & Consulting, the Global Systemic Scleroderma Treatment Market Size to grow from USD 1,520.1 million in 2021 to USD 2259.0 million by 2030, at a CAGR of 4.5% during the forecast period. Systemic scleroderma is an autoimmune disease that causes the skin and internal organs to harden and become thick. The exponential growth in the number of government initiatives and services available to promote knowledge about the illness and therapeutic options is a key element driving the development of systemic scleroderma treatments and the demand for them. The Asia Pacific is expected to grow the fastest during the forecast period.

Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/1224

The endothelin receptor antagonists segment to account for the largest market size during the forecast period

Based on the drug type, the systemic scleroderma treatment market is categorized into immunosuppressors, calcium channel blockers, proton pump inhibitors, phosphodiesterase 5 inhibitors, endothelin receptor antagonists, prostacyclin analogs, and others. In 2021, the endothelin receptor antagonists segment dominated the market with the largest market share of 20% and market revenue of 304.02 million. Drugs belonging to the class known as endothelin receptor antagonists (ERA) are effective at blocking endothelin receptors, particularly type A receptors. This induces vasodilation, which may reduce blood pressure and improve blood flow to organs such as the kidney, liver, and brain. Ambrisentan, bosentan, sitaxsentan, and macitentant are some of these alternatives. Both pulmonary arterial hypertension (PAH) and scleroderma are treated with these medications. Due to its effects on scleroderma, it is used excessively, leading to market growth.

Hospital pharmacies segment to hold a higher CAGR during the forecast period

Based on the…